Survival After Combining Stereotactic Body Radiation Therapy and Tyrosine Kinase Inhibitors in Patients With Metastatic Renal Cell Carcinoma

Survival After Combining Stereotactic Body Radiation Therapy and Tyrosine Kinase Inhibitors in Patients With Metastatic Renal Cell Carcinoma

BackgroundStereotactic body radiation therapy (SBRT) and tyrosine kinase inhibitors (TKIs) are effective treatments for metastatic renal cell carcinoma, but data on combining these two modalities are scarce. We aimed to investigate the survival outcomes of SBRT plus TKIs.MethodsData of patients trea...

Full description

Bibliographic Details
Main Authors: Yang Liu, Zhiling Zhang, Hui Han, Shengjie Guo, Zhuowei Liu, Mengzhong Liu, Fangjian Zhou, Pei Dong, Liru He
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-02-01
Series:Frontiers in Oncology
Subjects:
renal cell carcinoma
stereotactic body radiotherapy
tyrosine kinase inhibitors
survival
metastasis
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.607595/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.607595/full

Similar Items